Project cooperationUpdated on 22 April 2026
MMCR formulation platform - co-development, licensing & investment.
About
MMCR™ is a proprietary formulation technology designed to enable gastro‑resistant protection and prolonged‑release behavior in liquid oral formulations. While such performance characteristics are well established for solid dosage forms, they remain a major unmet need in liquid medicines.
Following our ongoing development of a liquid gastro‑resistant esomeprazole formulation for human use, we are expanding the MMCR™ platform into veterinary applications, with an initial focus on companion animals and horses. The objective is to apply the technology to new indications and active pharmaceutical ingredients (APIs), either through co‑development partnerships, licensing of the MMCR™ platform or investment.
Development Status
- Human program:
Liquid gastro‑resistant esomeprazole formulation under development. With first PoC in a human clinical study.
- Veterinary program:
Early stage, Evaluation of target APIs and animal‑specific use cases. Partner engagement for co‑development and licensing discussions
Stage
- TRL 5: Technology validation in relevant environment
Topic
- Animal Health
Type
- Research Collaboration
- Licensing Partner
- Commercialisation Partner
- Distribution Partner
- Investment Partner
Organisation
Courcelles, Belgium
Similar opportunities
Project cooperation
Nicolás Galmarini
CEO & Co-founder at NanoVet Biotech
Pamplona, Spain
Partnership
Drug development for companion animals.
Robert Kolodziejczyk
R&D Director at Green Zebras
Wroclaw, Poland
Investment
Accelerate preclinical and clinical development
Nicolás Galmarini
CEO & Co-founder at NanoVet Biotech
Pamplona, Spain